Journal of Neuro-Oncology

, Volume 78, Issue 2, pp 129–134

Inhibition of human Neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor Nimesulide

Authors

  • Bhupesh Parashar
    • Department of Radiation OncologyMontefiore Medical Center
    • Department of PathologyAlbert Einstein College of Medicine
    • Department of Radiation Oncology, Weill Cornell Medical Center,New York Presbyterian Hospital
Laboratory Investigation

DOI: 10.1007/s11060-005-9079-8

Cite this article as:
Parashar, B. & Shafit-Zagardo, B. J Neurooncol (2006) 78: 129. doi:10.1007/s11060-005-9079-8

Summary

Neuroblastoma is the most common solid tumor of infants and carries a poor prognosis especially in advanced stages. The present recommended therapies carry a high risk of side effects that is associated with long-term morbidity. We evaluated the efficacy of a low dose of the selective cyclooxygenase-2 inhibitor Nimesulide in preventing human Neuroblastoma tumor growth in Severe Combined Immune-deficient mice. Mice containing established tumors (SH-SY5Y cells) treated with 20 mg/kg Nimesulide every 4th day beginning on day 1 of cell injections resulted in a 65% reduction of tumor growth compared to the DMSO treated control mice (P<0.05) but did not significantly reduce tumor growth when Nimesulide was started once tumors reached 1cm. There was a reduction in the level of cyclooxygenase-2 protein and induction of effecter caspases in tumors treated with Nimesulide. However, there was no change in the levels of X-Inhibitor-of-Apoptosis-Protein, Smac/Diablo, or proteins of the PI3/Akt pathway following Nimesulide treatment. In Conclusion, low doses of Nimesulide can potentially be used as a chemopreventive agent for human Neuroblastoma.

Keywords

Cox-2NeuroblastomaNimesulideSCIDXIAP

Copyright information

© Springer Science+Business Media, Inc. 2006